• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH

ALTERITY THERAPEUTICS LIMITED - Charts / Financials

6.25% ! 0.8¢
Market Cap $108.7M  !
Healthcare Biotechnology
Add to My Watchlist

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 16.10pm 10/02/2026 (20 minute delay) ?
Day
Open 0.8¢   Day High 0.8¢   Day Low 0.7¢
Daily Volume 12984397
Bids   Sellers
Number Price Volume   Number Price Volume
0 0.7¢ 40017336   0 0.8¢ 21401

Directors & Senior Management

Ms. Abby Macnish Niven CFO & Company Secretary
Prof. Colin Louis Masters Member of Research & Development Advisory Board
Dr. David A. Stamler CEO & Director
Dr. Ira Shoulson Chairman of Research & Development Advisory Board
Mr. Julian Barbaczy Non-Executive Chair
Mr. Lawrence B. Gozlan Non-Executive Director
Mr. Peter Ashley Marks Non-Executive Independent Director
Dr. Robert Cherny Head of Research
Dr. Rudolph Emile Tanzi Chief Scientific Advisor and Member of Research & Development Advisory Board
Dr. Steven D. Targum Chief Medical Advisor

Data source: ADVFN

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.8¢ 		Change
-0.001(6.25%) 		Mkt cap ! $108.7M
Open High Low Volume
0.8¢ 0.8¢ 0.7¢ 12.98M

Buyers (Bids)

Vol. Price($)
40017336 0.7¢
 

Sellers (Offers)

Price($) Vol.
0.8¢ 21401
Last trade - 16.10pm 10/02/2026 (20 minute delay) ?

Top Stories

'Red hot': Omega Oil & Gas heads up new international Taroom Trough JV

Omega Oil & Gas continues to expand its major interests in the rich Taroom Trough area of Queensland with a slanted joint venture.
ASX Today: Uranium back up as Mag7 turn into nuclear companies, XJO travels sideways, EOS bites back We were flat for the most of the day after a ripper Monday session saw last week’s Friday tank more or less completely erased, definitely the case out the gate on Tuesday. But as we got through the session, that initial strength did subdue, the XJO up a fifth of a percent heading ...
Raptor pounces on visual copper mineralisation at Chester Raptor Metals has intersected zones of significant copper mineralisation at the Chester project in Canada.
Castile raises Rover 1 BFS funds; has 'fast-tracked' plans for April exploration drilling Castile Resources (ASX: CST) received strong support from a range investors and board and management for a successful placement.
Listen: HotCopper Wire Podcast #041 – Our first RBA rate hike since CY23 On the HotCopper Wire this week, JD and I unpack the RBA's first "hike" since CY23 and Trump's $12B stockpile, and call a "crypto winter."
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.